Lexaria Bioscience Files 8-K for Regulation FD Disclosure

TL;DR

**Lexaria Bioscience just filed a routine 8-K for compliance, no major news.**

AI Summary

Lexaria Bioscience Corp. filed an 8-K on January 4, 2024, primarily for Regulation FD Disclosure and to include Financial Statements and Exhibits. This filing is a routine update, indicating the company is maintaining compliance with SEC regulations by disclosing information that may be material to investors. For shareholders, this means the company is transparent and adhering to reporting standards, which can build confidence, though this specific filing doesn't reveal new operational or financial news.

Why It Matters

This filing demonstrates Lexaria Bioscience's commitment to regulatory compliance and transparency, which is crucial for maintaining investor trust and market integrity.

Risk Assessment

Risk Level: low — This 8-K is a standard compliance filing and does not introduce new financial or operational risks.

Analyst Insight

A smart investor would note this as a routine compliance filing, indicating no immediate operational or financial changes. It's a good sign of transparency but doesn't warrant any specific trading action based solely on this filing.

Key Players & Entities

• Lexaria Bioscience Corp. (company) — the registrant filing the 8-K
• Nevada (company) — state of incorporation for Lexaria Bioscience Corp.
• 001-39874 (dollar_amount) — SEC file number for Lexaria Bioscience Corp.
• January 4, 2024 (date) — date of earliest event reported and filing date

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share Warrants to Purchase Common

Filing Documents

• lxrp_8k.htm (8-K) — 27KB
• lxrp_ex991.htm (EX-99.1) — 36KB
• lxrp_ex991img1.jpg (GRAPHIC) — 20KB
• lxrp_ex991img2.jpg (GRAPHIC) — 23KB
• 0001640334-24-000007.txt ( ) — 250KB
• lxrp-20240104.xsd (EX-101.SCH) — 6KB
• lxrp-20240104_lab.xml (EX-101.LAB) — 14KB
• lxrp-20240104_cal.xml (EX-101.CAL) — 1KB
• lxrp-20240104_pre.xml (EX-101.PRE) — 9KB
• lxrp-20240104_def.xml (EX-101.DEF) — 2KB
• lxrp_8k_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On January 4, 2024, Lexaria Bioscience Corp. (" Lexaria ") announced the final results from its human pilot study (the " Study ") which evaluated a DehydraTECH processed dosage of the glucagon-like peptide-1 (" GLP-1 ") drug semaglutide found in Rybelsus against a parallel dosage of non-DehydraTECH processed Rybelsus. The Study was conducted in a university research center as a cross-over design over two study visits, one in November and the second in December, whereby all seven healthy subjects were dosed with each test article. Results from the Study indicate at all 19 blood point sample time points, that the DehydraTECH GLP-1 blood semaglutide level was higher than the Rybelsus control sample and that peak levels of semaglutide in blood were 43% higher in the DehydraTECH GLP-1 than in the Rybelsus control sample. Additional results indicated that: DehydraTECH GLP-1 reduced blood glucose to lower levels than the Rybelsus control sample and was much more effective at maintaining consistently reduced blood glucose levels even after eating a standardized meal at the 240-minute mark and a standardized snack at the 360-minute mark

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits 99.1 Press Release dated January 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEXARIA BIOSCIENCE CORP. /s/ Chris Bunka Chris Bunka CEO, Principal Executive Officer Date: January 4, 2024 3